Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ImmunityBio Inc. | ANKTIVA (QUILT-106) - (ResQ215B) | B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemia. | Phase 2 | Ongoing | Intravenous | Oncology |
| Immunocore Holdings plc | IMC-F106C (PRAME HLA-A02) with nivolumab - (PRISM-MEL-301) | First-line advanced cutaneous melanoma trial | Phase 3 | Ongoing | Intravenous | Oncology |
| Immunocore Holdings plc | KIMMTRAK (tebentafusp-tebn) - (ATOM) | Uveal melanoma | Phase 3 | Ongoing | Intravenous | Oncology |
| Immunocore Holdings plc | KIMMTRAK with or without anti-PD1 therapy - (TEBE-AM) | Melanoma | Phase 3 | Ongoing | Intravenous | Oncology |
| Immunome Inc. | AL101 - (ACCURACY) | Adenoid cystic carcinoma | Phase 2 | Trial Completed | intravenous | Oncology |
| Immunome Inc. | AL101 | T-cell acute lymphoblastic leukemia (T-ALL) | Phase 2 | Trial Discontinued | intravenous | Oncology |
| Immunome Inc. | AL102 - (RINGSIDE) | Desmoid tumors | NDA Filing | Data Released | Oral | Oncology |
| Immunovant Inc. | IMVT-1401 | Graves Ophthalmopathy | Phase 2a | Trial Completed | Subcutaneous | Opthalmic |
